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were pre-treatment biopsy/surgical specimens. Upon his-
tological review, 62 patients had high-grade astrocytomas 
(18 WHO grade III and 44 WHO grade IV patients), 8 had 
WHO grade II astrocytomas, and 2 had features of primi-
tive neuroectodermal tumour (PNeT). K27M-H3 muta-
tions were exclusively found in tumours with WHO grade 
II–IV astrocytoma histology. K27M-H3.1 and ACVR1 
mutations as well as AlT phenotype were only found in 
WHO grade III–IV astrocytomas, while PIK3CA muta-
tions and PDGFRA gains/amplifications were found in 
WHO grade II–IV astrocytomas. Approximately 1/3 of 
DIPg patients had leptomeningeal spread of their tumour. 
Further, diffuse invasion of the brainstem, spinal cord 
and thalamus was common with some cases showing 
spread as distant as the frontal lobes. These findings sug-
gest that focal radiation may be inadequate for some of 
these patients. Importantly, we show that clinically classic 
DIPgs represent a diverse histologic spectrum, including 
multiple cases which would fit WHO criteria of grade II 
astrocytoma which nevertheless behave clinically as high-
grade astrocytomas and harbour the histone K27M-H3.3 
mutation. This suggests that the current WHO astrocy-
toma grading scheme may not appropriately predict out-
come for paediatric brainstem gliomas.
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Introduction
Paediatric brainstem tumours diffusely infiltrative of the 
pons—diffuse intrinsic pontine gliomas (DIPg) are the 
most common type of brainstem glioma, accounting for 
60–80 % of these tumours [19]. They are currently the 
Abstract Diffuse intrinsic pontine glioma (DIPg) is the 
main cause of brain tumour-related death in children. In 
the majority of cases diagnosis is based on clinical and 
MrI findings, resulting in the scarcity of pre-treatment 
specimens available to study. Our group has developed 
an autopsy-based protocol to investigate the histologic 
and biologic spectrum of DIPg. This has also allowed 
us to investigate the terminal pattern of disease and gain 
a better understanding of what challenges we are facing 
in treating DIPg. Here, we review 72 DIPg cases with 
well documented clinical history and molecular data and 
describe the pathological features of this disease in rela-
tion to clinical and genetic features. Fifty-three of the 
samples were autopsy material (7 pre-treatment) and 19 
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number one cause of brain tumour-related death in chil-
dren with a median survival of approximately 10 months 
and <10 % 2-year survival [4, 13]. Due to the location of 
these lesions, surgical intervention is not an option and 
biopsies have rarely been conducted, with diagnosis based 
on radiologic features and clinical findings [21]. However, 
recent biopsy-based studies of DIPg have been safely con-
ducted and may open the door for future biopsy-informed 
clinical trials [18]. radiotherapy is the prevailing mode of 
treatment; however, it is mainly palliative, and clinical tri-
als over the last few decades have not demonstrated a sur-
vival benefit of adjuvant chemotherapy [6]. According to a 
recent review by Jansen et al. [9], there have been 55 clini-
cal trials since 1984, including 26 between 2007 and 2012, 
with no improved survival or prognosis when compared to 
radiation therapy alone.
Several studies into the underlying biology of DIPg 
over the last few years have demonstrated genetic signa-
tures commonly present in subsets of patients [5, 10, 16, 
17, 24, 26]. TP53 represents one of the most commonly 
mutated genes described in DIPg, present in 40–77 % of 
cases [5, 10]. Our group and others have demonstrated a 
high-frequency heterozygous mutation of histone H3.3 in 
DIPg at residue K27 [10, 24]. The mutation, resulting in 
replacement of a lysine with methionine (K27M), is pre-
sent in approximately 70 % of DIPgs versus 21 % of, 
largely midline thalamic, supratentorial gBMs [10, 22]. 
K27 is an important residue that can be either acetylated, 
methylated or ribosylated on all histone H3 variants [2, 
14, 15, 20]. Although the biological consequence of this 
mutation is still under investigation, given the high fre-
quency of this mutation involving a functionally impor-
tant, conserved residue, it is likely relevant for tumouri-
genesis. The roles of K27M-H3.3 in dysregulation of 
PrC2 complex member eZH2 and global decrease in 
H3K27me3 have been documented [1, 11]. Moreover, 
the mutation confers a worse overall survival compared 
to H3.3 wild-type patients and there are specific copy 
number alterations associated with the mutation including 
PDGFRA and PVT1/MYC locus gains and amplification, 
which are not seen in the wild-type patients [10]. While 
our understanding of some of the genetic underpinnings of 
DIPg has improved over the last few years, the assump-
tion has been that these represent brainstem gBMs and 
that low-grade histology seen in biopsy specimens rep-
resents sampling bias. Here, we describe the histopatho-
logical features of 72 DIPgs, the largest DIPg histologic 
series reviewed to date, and correlate it with clinical data 
as well as recurrent copy number alteration and mutation 
status of genes frequently affected in DIPg. These data 




Seventy-two infants and children diagnosed with DIPg 
between 1984 and 2012 were included in the study. Forty-
one were diagnosed and treated at the Hospital for Sick 
Children and 31 cases were referred from outside. The 
cooperating pathologists and institutions are listed in 
acknowledgements. Clinical presentation was consistent 
with DIPg including history of one or more of progres-
sive headache, vomiting, diplopia, unsteady gait, slurred 
speech, papilledema, cranial nerve palsies and signs of 
ataxia. Imaging characteristics were also in keeping with 
a diffuse pontine tumour, including a contrasting lesion on 
MrI with diffuse involvement of at least 50 % of the pons 
required for DIPg diagnosis. Thirty-five of the patients 
were female and 37 were male. The mean age of diagno-
sis for our cohort was 6.87 years (median 6.47 years; range 
0 days to 15.35 years). More than 80 % of patients were 
under the age of 10 at the time of diagnosis. The median 
survival was 0.83 years.
Chemotherapy, if any, varied based on protocols avail-
able at the time of presentation or progression and included 
temozolomide (Temodol), nimotuzumab (TheraCIM), tipi-
farnib (Zarnestra), retinoic acid, bevacizumab (Avastin), 
temsirolimus (Torisel) or cituxumab (IMC-A12).
radiotherapy data were available for 59 patients. Of 
these, all but 6 patients received focal radiation. Forty-eight 
patients received a dose of 54 gy over 30 fractions. One 
patient received 25 gy over 5 days. Three patients received 
56 gy and one patient received 59 gy of radiation. This 
same patient was re-irradiated. All clinical and molecular 
features of our DIPg cohort can be found in Table S1.
Histology and immunohistochemistry
All available surgical and autopsy materials were exam-
ined by routine haematoxylin and eosin (H&e) staining 
and as indicated, by immunohistochemical staining (IHC) 
for selected proteins (including MIB1, gFAP, p53, MAP2, 
NeuN, and nestin) using standard automated immunoper-
oxidase detection. 5 µm sections were cut from paraffin 
blocks and mounted on positively charged slides. Immu-
nodetection was performed with the automated Benchmark 
XT stainer (Ventana, Tucson, AZ) using the Ultraview Uni-
versal DAB Detection kit (Ventana). Slides were counter-
stained with haematoxylin II kit (Ventana). All cases were 
assigned a diagnosis and grade according to WHO crite-
ria. For 44 DIPg patients the entire brain or partial brain 
specimen with detailed autopsy report was available for 
examination, allowing extensive histological review of 
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tumour spread and statistical testing related to tumour dis-
semination. For the cases where entire brain was available, 
15–20 blocks were taken including approximately ten sec-
tions from the brainstem (medulla, pons and midbrain) as 
well as sections from the thalamus, basal ganglia, occipi-
tal lobe, temporal lobe, frontal lobe and deep white matter. 
Sections were examined and evaluated for extent of disease 
and presence of leptomeningeal and/or intraventricular dis-
semination. An additional nine autopsy cases referred from 
collaborating pathologists and institutions had insufficient 
autopsy material to evaluate leptomeningeal dissemina-
tion or distant tumour spread, but were evaluable for WHO 
diagnosis and grade and had material available for molecu-
lar diagnosis. A further 19 cases had available surgical pre-
treatment material and were only assessed for tumour grade 
and molecular analysis when sufficient biological material 
was available. Where applicable, pathological reports from 
referring pathologists were reviewed to corroborate histo-
pathological diagnosis of reviewed slides.
Molecular analysis
Fifty-one DIPg patients had sufficient biological material 
to perform targeted sequencing of H3F3A, HIST1H3B/C, 
PIK3CA, TP53 and ACVR1 using Fluidigm array and ion 
torrent chips (life Technologies). An additional 15 sam-
ples were sequenced for coding regions of H3F3A and 
HIST1H3B/C using Sanger fluorescence sequencing. The 
histone H3 and TP53 mutational status of a subset of these 
patients has previously been reported [10]. ACVR1 muta-
tions in a subset of these patients were previously described 
[3]. Alternative lengthening of telomeres was assessed as 
previously described by either terminal restriction fragment 
assay (TrF) [8] or C-circles [7].
Statistical analysis
Where applicable, statistical analysis was performed using 
SPSS v21 (IBM Corporation) or graphPad Prism 5 soft-
ware. Overall survival was estimated using the Kaplan–
Meier method and univariate assessments of Kaplan–Meier 
plots were tested using log rank. Unpaired two-tailed Stu-
dent’s t test was used for statistical testing of continuous 
scale data. p values ≤0.05 were considered to be signifi-
cant. Multivariate Cox proportional hazard models and sig-
nificance testing based on the Wald test (α = 0.05) were 
used for multivariate analysis. Statistical testing of lep-
tomeningeal dissemination, histone H3 mutations and 
histology were employed only for samples with sufficient 
clinical and molecular data. Statistics on leptomeningeal 
dissemination was not reported for biopsy patients as tis-
sue specimens were insufficient to determine the presence 
or absence of leptomeningeal disease.
Results
DIPg represents a histologic spectrum with grade not 
predictive of survival
Upon pathological review, 8 (11 %) samples were found to 
be diffuse astrocytoma WHO grade II (lgA), 18 (25 %) 
were anaplastic astrocytoma (AA, WHO grade III), 44 
(61 %) were glioblastoma (gBM, WHO grade IV), and 
2 (3 %) were primitive neuroectodermal tumours (PNeT, 
WHO grade IV). The PNeTs were more sharply demar-
cated from adjacent brain than the glial tumours, had no 
vascular endothelial proliferation or pseudopalisading 
necrosis and were immunonegative for gFAP (Fig. 1a). For 
17 of the gBM cases we reviewed the histology at multi-
ple levels of the brainstem as well as the thalamus, frontal 
cortex and metastatic disease and recorded the histologic 
grade of the tumour at that level (Table 1). Interestingly, 
this analysis showed that in 7 (40 %) cases the gBM his-
tology (vascular endothelial proliferation and necrosis) was 
limited to the pons while other levels showed WHO grade 
II or III histology. In no case was gBM histology present at 
all levels of the brain.
We had only one DIPg patient for whom biopsy and 
post-mortem material was available. This showed AA his-
tology on biopsy and gBM histology on autopsy. However, 
as described above it is quite possible to target lower-grade 
areas on biopsy, thus it is unclear if this represents true 
progression of disease. Future studies with larger series 
of matched biopsy/autopsy specimens would need to be 
conducted in order to determine if anaplastic progression 
occurs in DIPg between diagnosis and autopsy.
There was no significant difference in survival based on 
histology (Fig. 2a, p = 0.407). Median survival for patients 
with diffuse astrocytoma grade II, anaplastic astrocytoma 
and gBM was 0.88, 0.83 and 0.85 years, respectively. 
However, the association of age of diagnosis and tumour 
grade was significant (p = 0.040). The age of diagnosis for 
the glial tumours increased with tumour grade, as lgA, 
AA, and gBM had mean age of diagnosis at ages 4.19, 
6.67 and 7.61 years, respectively. This same trend was 
observed when biopsy samples and autopsy samples were 
analysed individually (Table S2).
DIPgs exhibit leptomeningeal spread and distant spread
For 44 patients sufficient tissue was available to assess 
extent of spread and the presence of disseminated dis-
ease. Seventeen of 44 patients (38.6 %) had leptomenin-
geal spread at autopsy (for example, see Fig. 1b). Further, 
11/44 (25 %) patients had tumour cells present beyond the 
brainstem (spinal cord and/or thalamic involvement; for 
example, see Fig. 1c), including four patients with tumour 
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cells diffusely infiltrating as far rostrally as the frontal lobe. 
There was no statistical correlation between presence of 
leptomeningeal dissemination and histologic grade. While 
it did not reach statistical significance, our data suggest that 
overall survival for patients with leptomeningeal spread 
was worse, averaging 7.9 months, whereas patients with-
out leptomeningeal spread had an average overall survival 
of 12.2 months (p = 0.09). Of the four cases which had 
spread to the frontal lobe at autopsy, three were gBM (two 
K27M-H3 and one WT-H3) and one was AA (WT-H3.3). 
Interestingly, the mean survival for the K27M-H3 mutant 
cases was 0.63 years and for the wild-type cases was 
1.84 years, although the numbers are too small to make 
definitive conclusions based on this. Similarly, the small 
number of patients with this distant spread at autopsy 
did not allow for statistical analysis of tumour grade and 
H3-mutational status. Histone mutation status was avail-
able for 15 patients with leptomeningeal dissemination, 
of which 8 (53 %) had the K27M-H3.3 mutation. gains of 
PDGFRA were detected in 4/8 DIPgs with K27M-H3.3 
Fig. 1  Histologic spectrum of DIPg. a PNeT, WT-H3: the tumour 
was not directly invasive and sharply demarcated from adjacent brain 
(upper right panel). On H&e the tumour cells have little cytoplasm 
with anaplastic nuclei and prominent nucleoli. There was no vascu-
lar endothelial proliferation and no pseudopalisading necrosis typi-
cal of high-grade astrocytomas. On IHC the tumour cells were nega-
tive for gFAP (lower right panel). b lgA, K27M-H3.3: On H&e 
this was an infiltrative astrocytic tumour with no high-grade features 
(WHO grade II). There was no vascular endothelial proliferation, 
necrosis and very few mitoses (upper left panel). less than 1 % of 
tumour cells were positive for MIB1/Ki-67 (upper right panel). 
There was leptomeningeal spread of the tumour and an exophytic 
component involving both the pons and the medulla (lower panels). 
c gBM, K27M-H3.3: at autopsy this tumour has classic gBM fea-
tures throughout the pons (upper left and right panels). There was 
diffuse intraparenchymal tumour infiltration into the thalamus (lower 
left panel) and cervical cord (lower right panel). d gBM, WT-H3.3: 
on autopsy, H&e staining revealed histology consistent with that of 
gBM; including pseudopalisading necrosis (upper left panel) and 
vascular endothelial proliferation (upper right panel). There was dif-
fuse intraparenchymal infiltration of the tumour into the midbrain 
(lower right panel)
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mutation and leptomeningeal dissemination. TP53 muta-
tion status was available for 11 patients with leptomenin-
geal disease. Six of these patients had TP53 mutations. 
One DIPg patient with leptomeningeal disease (gBM 
histology) had a p.gly328Val substitution in ACVr1 and 
one patient (lgA histology) had a p.glu545gly alteration 
in PIK3CA. There was no statistical difference in the fre-
quency of PIK3CA mutations between disseminated and 
non-disseminated cases.
K27M-H3.3 mutations and histology
Tumour tissue from the pons of 66 DIPg patients was 
screened for K27M mutation in histone H3 as previously 
described [10]. 42/66 (64 %) were found to be mutated for 
K27M-H3.3, with an additional eight patients with K27M-
H3.1 mutations (12 %). Mutant allele frequencies from 
deep sequencing suggest histone mutations are heterozy-
gously present in all tumour cells. Of the 14 biopsy tested 
for histone mutations, 7 (50 %) were mutated for K27M-
H3.3 and none had histone H3.1 mutations. Of the 52 
autopsy cases tested for histone H3 mutations, 35 (67 %) 
were mutated for K27M-H3.3 and 8 (15 %) were mutated 
for K27M-H3.1. We previously performed survival anal-
ysis in a subset of these DIPg patients based on histone 
mutation status [10]. In this larger series, the observation 
that patients with K27M mutation in either histone H3.1 
or H3.3 have worse overall survival compared to patients 
with no histone mutations remains significant (Fig. 2b, 
log rank, p = 0.0026). On multivariate analysis (Cox 
Table 1  WHO diagnosis of 
diffuse intrinsic pontine glioma 
by tumour location
GBM glioblastoma grade IV, AA 
anaplastic astrocytoma grade 
III, DA diffuse astrocytoma 
grade II
Autopsy cases Pons Medulla Midbrain Thalamus Frontal lobe Mets
DIPg03 gBM DA AA DA – –
DIPg04 gBM AA AA DA – –
DIPg05 gBM gBM AA AA – gBM
DIPg06 gBM DA gBM – – gBM
DIPg07 gBM DA gBM AA – –
DIPg08 gBM AA gBM – – –
DIPg18 gBM AA AA AA – –
DIPg19 AA AA AA AA – gBM
DIPg24 gBM AA AA – – –
DIPg27 gBM AA gBM AA – –
DIPg58 gBM AA gBM gBM DA –
DIPg59 gBM gBM gBM gBM AA –
DIPg60 gBM DA AA – – –
DIPg61 gBM AA AA AA – –
DIPg62 gBM AA AA DA – –
DIPg66 gBM AA gBM gBM AA –
DIPg78 gBM AA gBM – – –
Fig. 2  Histone mutations but not histologic grade predicts survival of 
DIPg patients. a Kaplan–Meier analysis of DIPg based on tumour 
grade and histology reveals there is no significant difference in sur-
vival based on histologic diagnosis (p = 0.407). b DIPg patients with 
K27M-H3 mutation (red) have worse overall survival as compared to 
wild-type H3 DIPg patients (green) as determined by Kaplan–Meier 
analysis (log rank, p = 0.0026)
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regression), which included histone mutational status, 
age of diagnosis, histological grade and sex, only histone 
mutation status was determined to be a significant pre-
dictor of overall survival with a hazard ratio of 2.8 (95 % 
confidence intervals, 1.35–5.78, p = 0.006, Table 2). DIPg 
patients who had wild-type H3 were diagnosed at a sig-
nificantly younger age than patients with K27M-H3 (wild-
type 4.84 years ± 4.13 vs. K27M-H3 7.36 years ± 3.31, 
p = 0.018). There was also correlation between histologic 
grade and mutational status. eighty-eight percent of gBMs 
harboured a K27M mutation in H3 versus 60 % of AAs 
and 71 % of lgA. K27M-H3.3 was found at a statistically 
higher ratio in gBM patients (78 %) than patients with AA 
histology (33 %) (p = 0.0016). The association of ana-
plastic astrocytoma histology and K27M-H3.1 mutations 
approached significance (p = 0.058). All K27M mutant 
tumours were glial (tumours with PNeT histology were 
wild-type), but represented a spectrum of WHO grades 
(II–IV). There was no correlation between K27M-muta-
tion status and leptomeningeal spread. Some patients were 
wild-type for H3.3 yet exhibited features of high-grade 
astrocytic tumours such as pseudopalisading necrosis, 
vascular endothelial proliferation and mitoses (Fig. 1d). 
Interestingly, despite typical high-grade glioma features, 
patients who were wild-type for H3 with gBM histology 
survived significantly longer than patients mutated for 
K27M with gBM histology (mean survival of 1.99 years 
vs. 0.96 years; p = 0.026). Conversely, some DIPg 
patients exhibited low-grade tumours with low prolifera-
tive index, yet were mutated for K27M-H3.3 (Fig. 1b) and 
exhibited a clinical course typical of high-grade gliomas. 
DIPg with grade II and III histology carrying the muta-
tion do just as poorly as gBM. The overall survival of 
K27M-H3.3 tumours with grade II and III histology was 
0.82 ± 0.47 years compared to 0.91 ± 0.77 years for 
K27M-H3.3 grade IV tumours (p > 0.05). Patients with 
WHO grade II diffuse astrocytomas, but wild-type for H3 
survived longer than K27M-H3.3 mutant WHO grade II 
astrocytomas. Histologically, these cases all had similar 
features of diffusely infiltrating astrocytic tumour with rare 
to no mitotic figures, low MIB1, diffuse gFAP immunopo-
sitivity and rare to no P53 immunopositivity. Most DIPgs 
were positive for gFAP, with more diffuse staining present 
in the grade II lesions and no gFAP immunopositivity pre-
sent in DIPg with PNeT histology.
DIPg histologic subgroups have unique genetic signatures
DIPg patients, although not significantly differing in 
their overall survival when based on histology and tumour 
grade, do show clinical and genetic alterations associ-
ated with histology. Sex differences were noted between 
the different histologies with gBM patients having a 2:1 
male to female ratio. This trend was opposite in anaplastic 
astrocytomas. Mutations and copy number alterations in 
genes known to be associated with DIPg were also differ-
ent among histologic subgroups. DIPg with gBM and AA 
histology had 65 and 25 % incidence of TP53 mutations, 
respectively, while no TP53 mutations were found in low-
grade astrocytoma DIPg patient tumours. Immunostaining 
for P53 did not correlate with TP53 mutation status, possi-
bly a result of unreliable results from post-mortem tissue. 
In addition, 50 % of DIPg with both gBM and AA histol-
ogy had deletion of one copy of TP53. As with mutations, 
no grade II DIPg had this alteration. A similar association 
was seen with activating mutations of ACVR1, where 20 
and 25 % of patients with gBM and AA histology had 
these mutations, respectively, whereas grade II DIPg 
and DIPg with PNeT histology did not harbour ACVR1 
mutations. PIK3CA mutations were present in 14.3 % of 
DIPgs, including WHO grade II-IV astrocytomas but not 
PNeTs. Similarly, PDGFRA copy number gains were 
seen in between 36 and 43 % of patients among all astro-
cytic histologies of DIPg and not in any PNeT. Alternate 
lengthening of telomeres (AlT) phenotype was seen in 
28 and 17 % of gBM and AA patients but not in lgA or 
PNeT DIPg patients (Fig. 3).
Discussion
Our results highlight the clinicopathological heterogene-
ity of DIPg and describe the relationship between histol-
ogy, leptomeningeal dissemination clinical outcome and 
molecular features. Based on WHO guidelines, DIPg have 
histology corresponding to grade II, grade III and grade IV 
tumours. Several cases with typical MrI and symptoms 
at presentation had histologies on autopsy that would not 
be considered “classic” for DIPg such as PNeT or lgA. 
Previous case studies have reported DIPg with PNeT his-
tology [23]. As in our cases, they described these tumours 
as having poorly differentiated cells, with scant cytoplasm 
and round nuclei. Interestingly, on gene expression profil-
ing, these tumours resembled supratentorial PNeT [23]. 
Patients in our series who were found at autopsy to have 
PNeT were diagnosed as DIPg based on standard criteria 
Table 2  Multivariate Cox regression analysis
Age Dx age of diagnosis, HR hazard ratio, CI confidence interval
Variables Hr p value lower 95 % CI Upper 95 % CI
K27M-H3 2.793 0.006 1.350 5.777
Histology 0.808 0.222 0.574 1.138
Age Dx 1.016 0.693 0.940 1.097
Sex 1.267 0.412 0.720 2.231
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including MrI and clinical presentation. These patients 
had clinical course of what is expected in the spectrum for 
“classical” DIPg and while an argument can be made that 
PNeT tumours of the brainstem should not be included as 
pontine gliomas, the purpose of our study was to investigate 
the molecular and histologic spectrum of what is clinically 
called DIPg. If biopsy becomes standard and diagnosis 
incorporates histologic and molecular criteria, these entities 
may be given an alternate designation.
Although there is a wide distribution of tumour grade 
and histology among DIPg, these alone are not a predic-
tor of survival. A previous clinicopathological study by 
Yoshimura et al. [25] of 40 diffuse brainstem tumours (33 
paediatric and 7 adult) reported a significant difference in 
overall survival between gBM and AA patients. This dif-
ference may be the result of inclusion of adult patients in 
this cohort. When considering only the paediatric popu-
lation of the previous study, only four patients with AA 
and one patient with lgA histology were described and 
the K27M-H3.3 status, which defines clinically relevant 
subgroups of DIPg [10], was not known. We found some 
association between histologic grade (gBM grade IV) and 
H3.3 mutational status, however, K27M-mutated tumours 
are found in DIPg with grade II, III and IV astrocytoma 
histology (Fig. 3). Tumours with lower-grade histology car-
rying the H3.3 mutation had overall survival comparable to 
that of grade IV gBM tumours. While patients with high-
grade tumours wild-type for H3.3 had overall survival com-
parable to patients with wild-type low-grade astrocytomas. 
K27M mutation testing may be helpful for biopsy specimen 
diagnosis, particularly given the potential histologic intratu-
moural heterogeneity observed in DIPg, as some tumours 
with classic gBM histology possess grade II or grade III 
histology areas, which may be targeted on biopsy. A major-
ity of these heterogeneous cases had features of classic 
gBM in the pons, including vascular endothelial prolifera-
tion and necrosis; however, when sampling the midbrain or 
thalamus, these features were not present and histology was 
consistent with lgA or AA. While wild-type status does 
not imply a better survival (for example, the PNeT-like 
tumours were wild-type for H3.3 and had poor outcome), 
the presence of a K27-H3 mutation is associated with poor 
outcome, despite histologic appearance. With advent of 
biopsy-driven clinical trials [12], K27M mutational status 
may be pivotal in trial design, particularly when a tumour is 
classified as a grade II due to limited biopsy specimen.
Fig. 3  DIPg histologic subgroups have some unique clinical and molecular features including mean age of diagnosis, sex, H3.3 and H3.1 muta-
tions, TP53 mutations and deletions, ACVR1 mutations, PDGFRA gains/amplifications and alternative lengthening of telomeres (AlT)
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Distribution of PDGFRA gains/amplification as well 
as PIK3CA mutations was similar among all astrocytic 
tumours, irrespective of grade, whereas AlT phenotype 
and mutations in TP53 and ACVR1 were only observed in 
tumours with AA and gBM histologies. None of the PDG-
FRA gains/amplifications, PIK3CA mutations, AlT phe-
notype or ACVR1 mutations were found in tumours with 
PNeT histology.
Thirty-eight percent of patients exhibited leptomenin-
geal spread of their tumour. The prevalence of leptomenin-
geal dissemination and distant tumour spread in our series 
of patients was similar to that reported previously [25]. 
We found no association with leptomeningeal dissemina-
tion and histology. The frequency of certain molecular 
features common amongst DIPg such as histone H3 muta-
tions, PDGFRA gains/amplifications, ACVR1 and PIK3CA 
mutations were not enriched in patients with leptomenin-
geal dissemination. Interestingly, none of the patients with 
leptomeningeal dissemination were found to have AlT 
phenotype. Diffuse tumour invasion of the brainstem was 
common among all of the DIPgs; with 25 % diffusely 
involving the upper cervical cord and thalamus. Some 
patients exhibited distal spread as far as the frontal lobes. 
This observation may be critical for clinical decision-
making, as focal radiation may be inadequate for patients 
with leptomeningeal and/or extra-brainstem spread. These 
patients may benefit from new treatment strategies targeted 
towards inhibiting tumour infiltration rather than prolif-
eration, especially since some of these very infiltrative 
tumours exhibit few mitoses and scarce MIB1 positivity. 
Conversely, on autopsy two patients had severe radiation 
necrosis of the brainstem with several other patients show-
ing mild to moderate radiation necrosis.
Based on the histologic spectrum of DIPg as well as 
the prognostic and therapeutic implications of K27M-H3, 
our findings argue for testing H3-mutation status of biopsy 
specimens at diagnosis. This important genetic informa-
tion could be rapidly integrated into the clinical practice, 
particularly in atypical DIPg, such as those with PNeT 
histology or low-grade lesions with mutant histone H3 
that have aggressive clinical course not typically encoun-
tered in supratentorial lgA. Importantly, the WHO grading 
scheme does not predict outcome in DIPg patients. New 
therapeutic approaches need to incorporate molecular and 
histological data in order to achieve maximum benefit for 
DIPg patients.
Acknowledgments We would like to thank Dr. Anne Bendel (Chil-
dren’s Hospital Minneapolis), Drs. Jennifer Chang and lucie lafay-
Cousin (University of Calgary), Drs. Sandra Dunn, Juliette Hukin 
and Chris Dunham (BC Children’s Hospital), Dr. Katrin Scheine-
mann (McMaster Children’s Hospital), Dr. Jean Mchaud (Children’s 
Hospital of eastern Ontario), Drs. Shayna Zelcer and David ram-
say (london Health Sciences Centre), Dr. Javad Nazarian (george 
Washington University), Dr. Jason Fangusaro (Children’s Hospital of 
Chicago), Dr. Matthias Karajannis (NYU langone Medical Center), 
Dr. Nicholas Foreman (University of Colorado), Drs. Julia Hegert and 
Amy Smith (Arnold Palmer Hospital for Children), Dr. Mark Souwei-
dane (Weill Cornell Medical College) and Dr. Jason Cain (Monash 
Institute of Cancer research) for providing us with DIPg biological 
material for this study. This work was supported by an operating grant 
from the National Brain Tumor Society and the Canadian Institutes of 
Health research [MOP 115004]. Pawel Buczkowicz is a recipient of 
CIHr Doctoral Frederick Banting and Charles Best Canada graduate 
Scholarships award.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution license which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Bender S, Tang Y, lindroth AM, Hovestadt V, Jones DT, Kool 
M, Zapatka M, Northcott PA, Sturm D, Wang W, radlwimmer 
B, Hojfeldt JW, Truffaux N, Castel D, Schubert S, ryzhova M, 
Seker-Cin H, gronych J, Johann PD, Stark S, Meyer J, Milde T, 
Schuhmann M, ebinger M, Monoranu CM, Ponnuswami A, Chen 
S, Jones C, Witt O, Collins VP, von Deimling A, Jabado N, Puget 
S, grill J, Helin K, Korshunov A, lichter P, Monje M, Plass 
C, Cho YJ, Pfister SM (2013) reduced H3K27me3 and DNA 
hypomethylation are major drivers of gene expression in K27M 
mutant pediatric high-grade gliomas. Cancer Cell 24(5):660–672. 
doi:10.1016/j.ccr.2013.10.006
 2. Bernstein Be, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff 
J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch r, Wagschal 
A, Feil r, Schreiber Sl, lander eS (2006) A bivalent chroma-
tin structure marks key developmental genes in embryonic stem 
cells. Cell 125(2):315–326. doi:10.1016/j.cell.2006.02.041
 3. Buczkowicz P, Hoeman C, rakopoulos P, Pajovic S, letourneau 
l, Dzamba M, Morrison A, lewis P, Bouffet e, Bartels U, Zuc-
caro J, Agnihotri S, ryall S, Barszczyk M, Chornenkyy Y, Bour-
gey M, Bourque g, Montpetit A, Cordero F, Castelo-Branco P, 
Mangerel J, Tabori U, Ho KC, Huang A, Taylor Kr, Mackay 
A, Bendel Ae, Nazarian J, Fangusaro Jr, Karajannis MA, Zag-
zag D, Foreman NK, Donson A, Hegert JV, Smith A, Chan J, 
lafay-Cousin l, Dunn S, Hukin J, Dunham C, Scheinemann K, 
Michaud J, Zelcer S, ramsay D, Cain J, Brennan C, Souweidane 
MM, Jones C, Allis CD, Brudno M, Becher O, Hawkins C (2014) 
genomic analysis of diffuse intrinsic pontine gliomas identifies 
three molecular subgroups and recurrent activating ACVr1 muta-
tions. Nat genet 46(5):451–456. doi:10.1038/ng.2936
 4. Freeman Cr, Perilongo g (1999) Chemotherapy for brain stem 
gliomas. Childs Nerv Syst 15(10):545–553
 5. grill J, Puget S, Andreiuolo F, Philippe C, MacConaill l, Kieran 
MW (2012) Critical oncogenic mutations in newly diagnosed 
pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 
58(4):489–491. doi:10.1002/pbc.24060
 6. Hargrave D, Bartels U, Bouffet e (2006) Diffuse brainstem gli-
oma in children: critical review of clinical trials. lancet Oncol 
7(3):241–248
 7. Henson JD, Cao Y, Huschtscha lI, Chang AC, Au AY, Pickett 
HA, reddel rr (2009) DNA C-circles are specific and quantifi-
able markers of alternative-lengthening-of-telomeres activity. Nat 
Biotechnol 27(12):1181–1185. doi:10.1038/nbt.1587
 8. Herbert BS, Shay JW, Wright We (2003) Analysis of telomeres 
and telomerase. Current protocols in cell biology/editorial board, 
581Acta Neuropathol (2014) 128:573–581 
1 3
Juan S Bonifacino et al. Chapter 18: Unit 18 16. doi:10.1002/047
1143030.cb1806s20
 9. Jansen MH, van Vuurden Dg, Vandertop WP, Kaspers gJ 
(2012) Diffuse intrinsic pontine gliomas: a systematic update 
on clinical trials and biology. Cancer Treat rev 38(1):27–35. 
doi:10.1016/j.ctrv.2011.06.007
 10. Khuong-Quang DA, Buczkowicz P, rakopoulos P, liu XY, Fon-
tebasso AM, Bouffet e, Bartels U, Albrecht S, Schwartzentruber 
J, letourneau l, Bourgey M, Bourque g, Montpetit A, Bourret 
g, lepage P, Fleming A, lichter P, Kool M, von Deimling A, 
Sturm D, Korshunov A, Faury D, Jones DT, Majewski J, Pfis-
ter SM, Jabado N, Hawkins C (2012) K27M mutation in his-
tone H3.3 defines clinically and biologically distinct subgroups 
of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 
124(3):439–447. doi:10.1007/s00401-012-0998-0
 11. lewis PW, Muller MM, Koletsky MS, Cordero F, lin S, 
Banaszynski lA, garcia BA, Muir TW, Becher OJ, Allis 
CD (2013) Inhibition of PrC2 activity by a gain-of-func-
tion H3 mutation found in pediatric glioblastoma. Science 
340(6134):857–861. doi:10.1126/science.1232245
 12. MacDonald TJ (2012) Diffuse intrinsic pontine glioma (DIPg): 
time to biopsy again? Pediatr Blood Cancer 58(4):487–488. 
doi:10.1002/pbc.24090
 13. Maria Bl, rehder K, eskin TA, Hamed lM, Fennell eB, Quis-
ling rg, Mickle JP, Marcus rB Jr, Drane We, Mendenhall NP 
et al (1993) Brainstem glioma: I. Pathology, clinical features, and 
therapy. J Child Neurol 8(2):112–128
 14. Meissner A, Mikkelsen TS, gu H, Wernig M, Hanna J, 
Sivachenko A, Zhang X, Bernstein Be, Nusbaum C, Jaffe DB, 
gnirke A, Jaenisch r, lander eS (2008) genome-scale DNA 
methylation maps of pluripotent and differentiated cells. Nature 
454(7205):766–770. doi:10.1038/nature07107
 15. Messner S, Altmeyer M, Zhao H, Pozivil A, roschitzki B, gehrig 
P, rutishauser D, Huang D, Caflisch A, Hottiger MO (2010) 
PArP1 ADP-ribosylates lysine residues of the core histone tails. 
Nucleic Acids res 38(19):6350–6362. doi:10.1093/nar/gkq463
 16. Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian 
rg, Olson JM, geyer Jr, Chi SN, da Silva NS, Onar-Thomas A, 
Baker JN, gajjar A, ellison DW, Baker SJ (2011) genome-wide 
analyses identify recurrent amplifications of receptor tyrosine 
kinases and cell-cycle regulatory genes in diffuse intrinsic pon-
tine glioma. Journal of clinical oncology Official journal of the 
American Society of Clinical Oncology 29(30):3999–4006
 17. Paugh BS, Qu C, Jones C, liu Z, Adamowicz-Brice M, Zhang 
J, Bax DA, Coyle B, Barrow J, Hargrave D, lowe J, gajjar A, 
Zhao W, Broniscer A, ellison DW, grundy rg, Baker SJ (2010) 
Integrated molecular genetic profiling of pediatric high-grade gli-
omas reveals key differences with the adult disease. J Clin Oncol 
28(18):3061–3068. doi:10.1200/JCO.2009.26.7252
 18. Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, Andrei-
uolo F, Carvalho D, reis r, guerrini-rousseau l, roujeau T, 
Dessen P, richon C, lazar V, le Teuff g, Sainte-rose C, geo-
erger B, Vassal g, Jones C, grill J (2012) Mesenchymal transition 
and PDgFrA amplification/mutation are key distinct oncogenic 
events in pediatric diffuse intrinsic pontine gliomas. PloS One 
7(2):e30313. doi:10.1371/journal.pone.0030313
 19. ramos A, Hilario A, lagares A, Salvador e, Perez-Nunez A, 
Sepulveda J (2013) Brainstem gliomas. Semin Ultrasound CT 
Mr 34(2):104–112. doi:10.1053/j.sult.2013.01.001
 20. reynolds N, Salmon-Divon M, Dvinge H, Hynes-Allen A, Bal-
asooriya g, leaford D, Behrens A, Bertone P, Hendrich B (2012) 
NurD-mediated deacetylation of H3K27 facilitates recruitment 
of polycomb repressive complex 2 to direct gene repression. 
eMBO J 31(3):593–605. doi:10.1038/emboj.2011.431
 21. robison NJ, Kieran MW (2014) Diffuse intrinsic pontine glioma: 
a reassessment. J Neurooncol. doi:10.1007/s11060-014-1448-8
 22. Schwartzentruber J, Korshunov A, liu XY, Jones DT, Pfaff 
e, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, 
Hovestadt V, Albrecht S, Kool M, Nantel A, Konermann C, lin-
droth A, Jager N, rausch T, ryzhova M, Korbel JO, Hielscher T, 
Hauser P, garami M, Klekner A, Bognar l, ebinger M, Schuh-
mann MU, Scheurlen W, Pekrun A, Fruhwald MC, roggendorf 
W, Kramm C, Durken M, Atkinson J, lepage P, Montpetit A, 
Zakrzewska M, Zakrzewski K, liberski PP, Dong Z, Siegel P, 
Kulozik Ae, Zapatka M, guha A, Malkin D, Felsberg J, reif-
enberger g, von Deimling A, Ichimura K, Collins VP, Witt H, 
Milde T, Witt O, Zhang C, Castelo-Branco P, lichter P, Faury 
D, Tabori U, Plass C, Majewski J, Pfister SM, Jabado N (2012) 
Driver mutations in histone H3.3 and chromatin remodelling 
genes in paediatric glioblastoma. Nature 482(7384):226–231. 
doi:10.1038/nature10833
 23. Sufit A, Donson AM, Birks DK, Knipstein JA, Fenton lZ, 
Jedlicka P, Hankinson TC, Handler MH, Foreman NK (2012) 
Diffuse intrinsic pontine tumors: a study of primitive neuroecto-
dermal tumors versus the more common diffuse intrinsic pontine 
gliomas. J neurosurg Pediatr 10(2):81–88. doi:10.3171/2012.3.P
eDS11316
 24. Wu g, Broniscer A, Mceachron TA, lu C, Paugh BS, Becks-
fort J, Qu C, Ding l, Huether r, Parker M, Zhang J, gajjar A, 
Dyer MA, Mullighan Cg, gilbertson rJ, Mardis er, Wilson rK, 
Downing Jr, ellison DW, Zhang J, Baker SJ, St. Jude Children’s 
research Hospital-Washington University Pediatric Cancer 
genome P (2012) Somatic histone H3 alterations in pediatric dif-
fuse intrinsic pontine gliomas and non-brainstem glioblastomas. 
Nature genet 44(3):251–253. doi:10.1038/ng.1102
 25. Yoshimura J, Onda K, Tanaka r, Takahashi H (2003) Clinico-
pathological study of diffuse type brainstem gliomas: analysis of 
40 autopsy cases. Neurologia medico-chirurgica 43(8):375–382 
(discussion 382)
 26. Zarghooni M, Bartels U, lee e, Buczkowicz P, Morrison A, 
Huang A, Bouffet e, Hawkins C (2010) Whole-genome profiling 
of pediatric diffuse intrinsic pontine gliomas highlights platelet-
derived growth factor receptor alpha and poly (ADP-ribose) poly-
merase as potential therapeutic targets. J clin oncol 28(8):1337–
1344. doi:10.1200/JCO.2009.25.5463
